newsfilter
← Latest News
GlobeNewswire·

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ADELAIDE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators